Heart failure & cardiomyopathiesRandomised controlled trial
NOTIFY-HF
- Randomised controlled trial
- single-centre
- pragmatic
- pilot
Authors' conclusion
In this randomized pilot trial, a patient-facing HeartLogic-guided mHealth pathway was feasible, acceptable, and associated with lower alert burden, supporting evaluation in a larger multicenter trial.
Study context
- Population
- Adults with HF and a HeartLogic-capable ICDrandomised 1:1
- Participants
- 160 adults
- Comparison
- Intervention vs Control
- Interventionn = 81
- Controln = 79reference
- Primary endpoint
- Coprimary: feasibility/acceptability and HeartLogic recovery metrics
- Follow-up
- 12 to 24 months
Primary result
As reported in the abstract
median follow-up 1.82 years
Intervention vs ControlEstimate (95% CI)
HeartLogic alert incidence
IRR 0.78(0.62–0.99)
monitored days outside alert state (13% more)
RR 1.13(1.02–1.25)
- Symptom-screen completion during alerts
- 80%
Further findings
Patient response by alert tier
- Greater self-reported health care contact after red than amber alerts
Exploratory clinical outcomes
- Directionally favourable; study not powered for these endpoints
Original publication
NOTIFY-HF. JACC Heart Fail. Published 10 July 2026. doi:10.1016/j.jchf.2026.103184
Summarised from the published abstract; every number is checked against it